• Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Elicera Therapeutics

2,44 SEK

-3,94 %

Mindre end 1K følgere

ELIC

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Sammenligne
-3,94 %
-22,95 %
-61,47 %
-52,03 %
-58,26 %
-59,48 %
-21,74 %
-
-59,61 %

Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses.

Læs mere
Markedsværdi
162,84 mio. SEK
Aktieomsætning
1,74 mio. SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin
EPS og udbytte
Finanskalender
Alle
Analyse
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper

Omsætning og EBIT-margin

Omsætning t

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
21.8
2026

Delårsrapport Q2'26

27.11
2026

Delårsrapport Q3'26

16.2
2027

Årsrapport '26

Selskabsmeddelelsei går

Elicera Therapeutics: Elicera's Nomination Committee Proposes Margareth Jorvid as New Chair of the Board

Elicera Therapeutics
Selskabsmeddelelse3.6.2026, 15.01

Elicera Therapeutics: Elicera publishes annual report for 2025

Elicera Therapeutics
Selskabsmeddelelse1.6.2026, 15.46

Elicera Therapeutics: Elicera announces outcome of the rights issue

Elicera Therapeutics

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Pressemeddelelse25.5.2026, 07.10

Elicera Therapeutics announces that the final reporting and final payment from the EIC Accelerator for the CARMA study have been approved

Elicera Therapeutics
Pressemeddelelse19.5.2026, 08.10

DNB Carnegie Access: Elicera Therapeutics - Extended company presentation and Q&A

Elicera Therapeutics
Pressemeddelelse13.5.2026, 13.57

Elicera Therapeutics' CSO takes temporary leave to undergo medical treatment - Di Yu appointed Acting CSO

Elicera Therapeutics
Selskabsmeddelelse11.5.2026, 12.16

Elicera Therapeutics: Elicera publishes information document regarding the rights issue

Elicera Therapeutics
Pressemeddelelse21.4.2026, 18.53

DNB Carnegie Access: Elicera Therapeutics: Withdrawing fair value following rights issue announcement - Correction

Elicera Therapeutics
Pressemeddelelse21.4.2026, 09.15

DNB Carnegie Access: Elicera Therapeutics: Withdrawing fair value following rights issue announcement

Elicera Therapeutics
Selskabsmeddelelse21.4.2026, 06.31

Elicera Therapeutics carries out a rights issue of approximately SEK 73 million

Elicera Therapeutics
Selskabsmeddelelse21.4.2026, 06.01

Elicera Therapeutics AB (publ) Interim Report 1 January - 31 March 2026

Elicera Therapeutics
Pressemeddelelse20.3.2026, 07.53

Elicera Therapeutics Announces Swedish Cancer Society's Senior Investigator Award to Chief Development Officer Di Yu

Elicera Therapeutics
Pressemeddelelse13.3.2026, 05.48

DNB Carnegie Access: Elicera Therapeutics: Focused on the future of immuno-oncology

Elicera Therapeutics
Pressemeddelelse11.3.2026, 09.53

Elicera Therapeutics receives Notice of Allowance for Japanease patent protecting the ELC-401 CAR T-cell candidate

Elicera Therapeutics
Pressemeddelelse10.3.2026, 08.41

Elicera Therapeutics' Chief Scientific Officer Magnus Essand named Cancer Researcher of the Year 2026 by the Swedish Cancer Society (Cancerfonden)

Elicera Therapeutics
Selskabsmeddelelse6.3.2026, 07.30

Elicera Therapeutics reports complete metabolic response (CMR) and well tolerated treatment in first two patients of cohort 3 in CARMA study, bringing total CMR to 6 out of 8 treated patients

Elicera Therapeutics
Pressemeddelelse27.2.2026, 07.30

Elicera Therapeutics provides update on preclinical CAR T-cell program ELC-401 for glioblastoma: preclinical development concluded and clinical trial planning underway

Elicera Therapeutics
Pressemeddelelse18.2.2026, 12.57

Elicera Therapeutics to present ipdated CARMA study data on March 6, 2026, at the 10th Zurich Immuno-Oncology Conference

Elicera Therapeutics
Selskabsmeddelelse13.2.2026, 07.20

Elicera Therapeutics AB (publ) Year-End 1 January - 31 December 2025

Elicera Therapeutics
Pressemeddelelse11.2.2026, 13.32

Elicera Therapeutics announces abstract acceptance at ISCT 2026 Dublin: Complete metabolic response achieved in four of six patients with iTANK-armed ELC-301 in CARMA Lymphoma Study

Elicera Therapeutics